Gary E Archer
Overview
Explore the profile of Gary E Archer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
3548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swartz A, Congdon K, Nair S, Li Q, Herndon 2nd J, Suryadevara C, et al.
NPJ Vaccines
. 2021 Jan;
6(1):12.
PMID: 33462231
Personalized cancer vaccines targeting neoantigens arising from somatic missense mutations are currently being evaluated for the treatment of various cancers due to their potential to elicit a multivalent, tumor-specific immune...
2.
Gedeon P, Streicker M, Schaller T, Archer G, Jokinen M, Sampson J
PLoS One
. 2020 Aug;
15(7):e0236374.
PMID: 32735564
We recently reported the development of a fully-human, CD3-binding bispecific antibody for immunotherapy of malignant glioma. To translate this therapeutic (hEGFRvIII-CD3- bi-scFv) to clinical trials and to help further the...
3.
Suryadevara C, Desai R, Farber S, Choi B, Swartz A, Shen S, et al.
Clin Cancer Res
. 2018 Nov;
25(1):358-368.
PMID: 30425092
Purpose: Chimeric antigen receptor (CAR) T cells have shown promise against solid tumors, but their efficacy has been limited, due in part, to immunosuppression by CD4FoxP3 regulatory T cells (Tregs)....
4.
Suryadevara C, Desai R, Abel M, Riccione K, Batich K, Shen S, et al.
Oncoimmunology
. 2018 Jun;
7(6):e1434464.
PMID: 29872570
Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid tumors clinically. Intracerebral tumors may pose challenges...
5.
Gedeon P, Schaller T, Chitneni S, Choi B, Kuan C, Suryadevara C, et al.
Clin Cancer Res
. 2018 Apr;
24(15):3611-3631.
PMID: 29703821
Conventional therapy for malignant glioma fails to specifically target tumor cells. In contrast, substantial evidence indicates that if appropriately redirected, T cells can precisely eradicate tumors. Here we report the...
6.
Reap E, Suryadevara C, Batich K, Sanchez-Perez L, Archer G, Schmittling R, et al.
Cancer Res
. 2017 Nov;
78(1):256-264.
PMID: 29093005
Median survival for glioblastoma (GBM) remains <15 months. Human cytomegalovirus (CMV) antigens have been identified in GBM but not normal brain, providing an unparalleled opportunity to subvert CMV antigens as...
7.
Batich K, Reap E, Archer G, Sanchez-Perez L, Nair S, Schmittling R, et al.
Clin Cancer Res
. 2017 Apr;
23(8):1898-1909.
PMID: 28411277
Patients with glioblastoma have less than 15-month median survival despite surgical resection, high-dose radiation, and chemotherapy with temozolomide. We previously demonstrated that targeting cytomegalovirus pp65 using dendritic cells (DC) can...
8.
Mitchell D, Batich K, Gunn M, Huang M, Sanchez-Perez L, Nair S, et al.
Nature
. 2015 Mar;
519(7543):366-9.
PMID: 25762141
After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce immune responses. As such, autologous DCs generated ex vivo have been pulsed with tumour antigens and...
9.
Schuster J, Lai R, Recht L, Reardon D, Paleologos N, Groves M, et al.
Neuro Oncol
. 2015 Jan;
17(6):854-61.
PMID: 25586468
Background: The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term survival. Rindopepimut consists of the unique EGFRvIII...
10.
Miao H, Choi B, Suryadevara C, Sanchez-Perez L, Yang S, De Leon G, et al.
PLoS One
. 2014 Apr;
9(4):e94281.
PMID: 24722266
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is uniformly lethal. T-cell-based immunotherapy offers a promising platform for treatment given its potential to specifically target...